Holen Sie sich die Stockscreener-App
2.08
1.89%
-0.04
Schlusskurs vom Vortag:
$2.12
Offen:
$2.13
24-Stunden-Volumen:
123.00K
Relative Volume:
0.46
Marktkapitalisierung:
$78.55M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-8.82M
KGV:
-6.9333
EPS:
-0.3
Netto-Cashflow:
$-18.01M
1W Leistung:
+20.93%
1M Leistung:
-21.51%
6M Leistung:
+100.00%
1J Leistung:
+51.82%
1-Tages-Spanne:
$2.00
$2.14
1-Wochen-Bereich:
$1.63
$2.1578
52-Wochen-Spanne:
$0.7301
$3.15
Estrella Immunopharma Inc Stock (ESLA) Company Profile
Firmenname
Estrella Immunopharma Inc
Sektor
Branche
Telefon
(510) 318-9098
Adresse
5858 HORTON STREET, SUITE 370, EMERYVILLE
Vergleichen Sie ESLA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ESLA
Estrella Immunopharma Inc
|
2.08 | 80.06M | 0 | -8.82M | -18.01M | -0.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
444.64 | 110.88B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
726.21 | 72.79B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
890.11 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
404.46 | 54.85B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
189.85 | 41.41B | 447.02M | -1.18B | -906.14M | -6.1812 |
Estrella Immunopharma Inc Aktie (ESLA) Neueste Nachrichten
Estrella Immunopharma shares gain as CD19 cancer therapy progresses into phase II - MSN
Estrella Immunopharma (ESLA) Stock Analysis Report | Financials & Insights - Benzinga
Estrella’s EB103 advances to Phase II after positive safety data By Investing.com - Investing.com Nigeria
Estrella Immunopharma Advances STARLIGHT-1 Trial to Phase II - TradingView
Estrella Immunopharma stock rises as cancer therapy advances to Phase II - Investing.com Canada
Estrella’s EB103 advances to Phase II after positive safety data - Investing.com
Estrella advances Starlight-1 trial into phase II following positive DSMB recommendation - marketscreener.com
Estrella (NASDAQ: ESLA) passes DSMB; EB103 high-dose cohort reports 100% CR - Stock Titan
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation - Business Wire
Is Estrella Immunopharma Inc. stock a defensive play in 2025Portfolio Gains Summary & Daily Growth Stock Investment Tips - Newser
Here's Why We're Not Too Worried About Estrella Immunopharma's (NASDAQ:ESLA) Cash Burn Situation - Sahm
Estrella Immunopharma (NASDAQ:ESLA) Raised to “Hold” at Wall Street Zen - Defense World
Estrella Immunopharma (NASDAQ:ESLA) Raised to "Hold" at Wall Street Zen - MarketBeat
How Estrella Immunopharma Inc. stock benefits from global expansionInsider Buying & Free Technical Pattern Based Buy Signals - newser.com
Published on: 2025-11-19 23:49:15 - newser.com
Is Estrella Immunopharma Inc. stock oversold or undervaluedStock Surge & Free High Accuracy Swing Entry Alerts - newser.com
What data driven models say about Estrella Immunopharma Inc.’s futureJuly 2025 Highlights & Capital Protection Trade Alerts - newser.com
Is now a turning point for Estrella Immunopharma Inc.July 2025 Chart Watch & Advanced Technical Analysis Signals - newser.com
Is Estrella Immunopharma Inc. building a consolidation baseMarket Trend Review & Precise Buy Zone Tips - newser.com
Will Estrella Immunopharma Inc. stock gain from government policies2025 Key Lessons & AI Driven Stock Price Forecasts - newser.com
Published on: 2025-11-15 19:23:21 - newser.com
Is Estrella Immunopharma Inc. reversing from oversold territoryEntry Point & Step-by-Step Swing Trade Plans - newser.com
How to integrate Estrella Immunopharma Inc. into portfolio analysis tools - newser.com
Published on: 2025-11-14 10:46:07 - newser.com
10-Q: Quarterly report - 富途牛牛
Get in on Estrella Immunopharma Inc’s (ESLA) buy-in window today! - Setenews
Finanzdaten der Estrella Immunopharma Inc-Aktie (ESLA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.45%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):